α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. [electronic resource]
Producer: 20200527Description: 62 p. digitalISSN:- 2051-1426
- Antineoplastic Agents, Immunological -- pharmacology
- Biomarkers
- CD4 Lymphocyte Count
- Carcinoma, Squamous Cell -- drug therapy
- Cell Line, Tumor
- Drug Synergism
- Epithelial-Mesenchymal Transition
- Humans
- Immunohistochemistry
- Lymphocyte Count
- Lymphocytes, Tumor-Infiltrating -- immunology
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Smad3 Protein -- metabolism
- T-Lymphocytes, Helper-Inducer -- drug effects
- T-Lymphocytes, Regulatory -- drug effects
- Transforming Growth Factor beta -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.